Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.
Overexpression of ATP-binding cassette (ABC) drug transporters that actively efflux a variety of amphipathic compounds can cause multidrug resistance (MDR) in cancer cells, which is a major obstacle in the success of cancer chemotherapy. The development of synthetic small molecule compounds or the identification of natural products that block ABC transporter-mediated efflux has been the conventional approach used to combat MDR. The strategy of using chemosensitizers, however, has not been successful in clinical cancer chemotherapy. Therefore, alternative approaches to identify or to synthesize compounds that can induce selective toxicity in cancer cells overexpressing one or more ABC transporters have been undertaken. This review summarizes the recent advances in identifying strategies to restore sensitivity to chemotherapeutics in multidrug resistant cancer cells.
Wu
Chung-Pu
CP
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Calcagno
Anna Maria
AM
Ambudkar
Suresh V
SV
D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004337:Drug Carriers; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D034622:RNA Interference
D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D004337:Drug Carriers